Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Regeneron Pharmaceuticals
Related studies linked through entity extraction aliases.
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
- Status
- COMPLETED
- Phase
- PHASE3
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment
- Status
- COMPLETED
- Phase
- PHASE4
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
- Status
- COMPLETED
- Phase
- PHASE4
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
- Status
- COMPLETED
- Phase
- PHASE1
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
- Status
- COMPLETED
- Phase
- PHASE2
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
- Status
- COMPLETED
- Phase
- PHASE3
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Colorectal Cancer Metastatic
- Status
- COMPLETED
- Phase
- PHASE3
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
- Status
- UNKNOWN
- Phase
- PHASE4
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
- Status
- COMPLETED
- Phase
- PHASE3